Brand Intelligence Graph
Company Overview
About Aerska Therapeutics
Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.
Business Model & Competitive Advantage
The blood-brain barrier (BBB) is the primary obstacle to CNS gene silencing: RNA therapeutics that work in peripheral tissues cannot efficiently reach the brain because the BBB prevents most molecules from crossing from blood to brain tissue. Aerska's brain-shuttle technology uses receptor-mediated transcytosis — hijacking the brain's natural nutrient transport mechanisms — to deliver RNAi payloads to specific CNS targets without requiring intrathecal injection or viral vectors.
Competitive Landscape 2025–2026
Genetic forms of Alzheimer's (APOE4, PSEN1/2 mutations) and Parkinson's (LRRK2, SNCA mutations) are among the most genetically validated drug targets in neuroscience: the mutations that cause these diseases are known, the proteins they encode are well-characterized, and reducing their expression is the mechanistically justified therapeutic strategy. Aerska's focus on genetic forms provides a biomarker-selected patient population where clinical success probability is meaningfully higher than in unselected Alzheimer's and Parkinson's populations.
Key Differentiators
Emerging Innovator
Aerska Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Prime Medicine
Prime Medicine is a publicly-traded (Nasdaq: PRME) clinical-stage biotech developing Prime Editing — the most versatile and precise gene editing technology currently entering clinical trials, capable
Compare Aerska Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aerska Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aerska Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aerska Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →